None listed
Conditions
Brief summary
This observational study will examine rates of compliance with calcium and vitamin D doses prescribed to cancer patients who may benefit from taking these supplements due to the type of cancer treatment drugs they have been given. Who is it for? You may be eligible for this study if you are 18 or older, you are receiving cancer treatment(s) including Denosumab, Pamidronate or Zoledronic acid and you are attending one of the Icon Cancer Centres in Queensland for treatment. Study details All enrolled participants will be asked to complete a survey that includes questions about their current cancer treatment, and whether they have been prescribed calcium and vitamin D in addition to their cancer treatment. It is expected that the survey will take approximately 15 minutes to complete, and participants will be asked to complete this during a scheduled clinic visit, therefore additional study visits are not required. It is hoped this research will determine the current rate of calcium and vitamin D dose compliance in patients whose cancer treatment may have a negative impact on their bone health. It is hoped this study will also identify barriers that may make it difficult for patients to maintain their calcium and vitamin D doses and will then be able to make adjustments to address these barriers.
Interventions
An in-house quality audit was conducted at Icon Cancer Centre South Brisbane and Chermside sites in June 2018 which involved a survey that was performed with patients prescribed Denosumab for metastatic breast and prostate cancer which highlighted non-adherence to calcium and vitamin D supplementation. Of the 35 patients surveyed, 60% were compliant with their prescribed therapy. As the use of both calcium and vitamin D supplements are an integral part of patient treatment pathways, further rese
An in-house quality audit was conducted at Icon Cancer Centre South Brisbane and Chermside sites in June 2018 which involved a survey that was performed with patients prescribed Denosumab for metastatic breast and prostate cancer which highlighted non-adherence to calcium and vitamin D supplementation. Of the 35 patients surveyed, 60% were compliant with their prescribed therapy. As the use of both calcium and vitamin D supplements are an integral part of patient treatment pathways, further research is needed to identify true rates of compliance by analysing a larger patient group throughout more treatment sites in order to identify areas for improvement and barriers to patient compliance. The study will be expanded from the original audit scope to include patients receiving both RANK-L inhibitors and bisphosphonates for cancer related bone metastasis and also multiple myeloma. Data collection will be carried out over 12 months or until target patient number reached. Patients to complete ONE survey only. Patients will complete e-survey either face-to-face or via email link at home after completing e-consent. Patient's information pertaining to blood results will be collected from most recent blood results (via electronic sourcing in TotalCar), and also from bloods collected at the beginning of their treatment (day 1 of starting bone-resorptive therapy)
Sponsors
Icon Cancer Foundation
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients over the age of 18 treated at Icon Cancer Centre sites where Denosumab, Pamidronate or Zoledronic acid has been prescribed between August 2021 and recruitment period of 24 months in total or until goal participant numbers have been reached.
Exclusion criteria
Patients with hyperglycemia of malignancy; Patients with history of osteoporosis. Patients participating in other clinical trials
Outcome results
None listed